17 December 2018 - - Canadian contract research organisation Altasciences recently completed an important First-in-Human, Phase I, integrated adaptive clinical trial, including single and multiple ascending doses (SAD and MAD), Project Management, Bioanalysis, and Medical Writing, for sponsor Bellus Health, the company said.

Altasciences' contributions to the positive top-line results were significant. From recruitment of 90 subjects to management of all relevant aspects of this important FIH trial, Altasciences used a flexible and adaptive approach to fully meet the client's needs.

The company said its contributions allowed Bellus Health to make a well-informed decision to proceed with their promising drug candidate for chronic cough.

Altasciences conducts hundreds of early phase clinical trials annually.

The company is a mid-size contract research organisation with a unique focus on supporting drug development from lead candidate selection to proof of concept.

Altasciences encompasses Algorithme Pharma in Montreal, QC, Vince and AssociatesClinical Research in Kansas City, KS, Algorithme Pharma USA in Fargo, ND, and Altasciences Preclinical Services in Seattle, WA.

With over 25 years of industry experience, Altasciences provides preclinical and clinical solutions to an international customer base of biopharmaceutical companies.

Altasciences' full-service solutions offering in this critical stage of drug development includes preclinical safety testing, clinical pharmacology services, bioanalysis, medical writing, biostatistics, data management, and overall program management.